AstraZeneca (NASDAQ:AZN – Get Rating) was downgraded by research analysts at Kepler Capital Markets from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, The Fly reports.
Several other equities research analysts also recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised their target price on shares of AstraZeneca from £105 ($129.44) to £115 ($141.77) in a research note on Wednesday, April 6th. Barclays raised their price target on shares of AstraZeneca from £115 ($141.77) to £120 ($147.93) in a report on Thursday, April 14th. JPMorgan Chase & Co. raised their price target on shares of AstraZeneca from £100 ($123.27) to £120 ($147.93) in a report on Thursday, April 7th. DZ Bank raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Friday, February 11th. Finally, Credit Suisse Group raised their price target on shares of AstraZeneca from GBX 9,000 ($110.95) to £110 ($135.60) in a report on Friday, April 8th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $7,223.13.
AZN traded down $1.89 during trading on Wednesday, hitting $63.75. The stock had a trading volume of 321,546 shares, compared to its average volume of 7,749,243. The company has a market capitalization of $197.55 billion, a PE ratio of -199.21, a PEG ratio of 1.17 and a beta of 0.45. AstraZeneca has a twelve month low of $53.63 and a twelve month high of $71.70. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.76 and a current ratio of 1.16. The stock has a 50 day simple moving average of $65.65 and a two-hundred day simple moving average of $60.86.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MayTech Global Investments LLC purchased a new position in shares of AstraZeneca in the third quarter valued at approximately $25,000. Arlington Partners LLC acquired a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $25,000. Horan Securities Inc. acquired a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $26,000. DB Wealth Management Group LLC acquired a new stake in shares of AstraZeneca in the first quarter valued at approximately $26,000. Finally, Parkside Financial Bank & Trust increased its holdings in shares of AstraZeneca by 4,875.0% in the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock valued at $26,000 after purchasing an additional 390 shares during the last quarter. Hedge funds and other institutional investors own 20.46% of the company’s stock.
About AstraZeneca (Get Rating)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
- Dynatrace: Fundamentals are Positive While Being Punished
- Now’s The Time To Buy Disney (NYSE: DIS)
- 3 Small Caps With Big Return Potential
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.